Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytohesin-3 (CYTH3) is a guanine-nucleotide exchange factor (GEF) belonging to the cytohesin/PSCD protein family, characterized by an N-terminal coiled-coil motif, a central Sec7 GEF domain, and a C-terminal pleckstrin homology (PH) domain. It promotes guanine-nucleotide exchange on ARF GTPases (particularly ARF1 and ARF6), facilitating their activation by exchanging GDP for GTP. Cytohesin-3 plays a role in regulating Golgi structure and function, mediating protein sorting, membrane trafficking, and epithelial cell polarity. It localizes to multiple subcellular compartments, including the cytosol, plasma membrane, Golgi membrane, nucleoplasm, and cell junctions. Genetic and functional associations link CYTH3 to several biologically and clinically relevant processes, although no specific pharmacological modulators or approved interacting drugs are documented to date.
If targeted, drugs would be expected to inhibit guanine-nucleotide exchange activity on ARF1/ARF6, affecting vesicle trafficking and ARF signaling. This is an inference based on the established biological activity of the protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytohesin-3 (CYTH3).